Full metadata record
DC FieldValueLanguage
dc.creatorReboredo-Fuentes, C. (Cristian)-
dc.creatorGonzalez-Navarro, C.J. (Carlos Javier)-
dc.creatorLópez, A. (Andrés)-
dc.creatorIrache, J.M. (Juan Manuel)-
dc.date.accessioned2023-05-02T14:27:59Z-
dc.date.available2023-05-02T14:27:59Z-
dc.date.issued2022-
dc.identifier.citationReboredo-Fuentes, C. (Cristian); Gonzalez-Navarro, C.J. (Carlos Javier); Martínez-López, A.L. (Ana L.); et al. "Oral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in rats". International Journal of Pharmaceutics. 628, 2022, 122255es_ES
dc.identifier.issn0378-5173-
dc.identifier.urihttps://hdl.handle.net/10171/66139-
dc.description.abstractThe aim was to evaluate the effect of zein-based nanoparticles on the glucose homeostasis, following oral administration to Wistar rats. For this purpose, bare nanoparticles (NP, with tropism for the upper intestinal regions) and poly(ethylene glycol)-coated nanoparticles (NP-PEG), with the capability to reach the ileum and cecum of animals, were evaluated. Both formulations were spherical in shape, displaying sizes around 200 nm and a negative surface zeta potential. The oral administration of a single dose of these nanoparticles to animals (50 mg/kg) induced a significant decrease of the glycemia, compared control rats and in animals treated with the free protein (p < 0.001). Moreover, these nanoparticles improved the glycemic control against an intraperitoneal glucose tolerance test; particularly NP-PEG. These findings would be due to an increased release of glucagon-like peptide-1 (GLP-1) by L-cells, which are more abundant in distal regions of the intestine. In fact, the GLP-1 blood levels of animals treated with nanoparticles were significantly higher than controls (about 40 % and 60 % for NP and NP-PEG groups, respectively). This higher capability of NP-PEG, with respect to NP, to increase the release of GLP-1 and control glycemia would be related to its ability to reach the distal areas of the small intestine.es_ES
dc.description.sponsorshipCristian Reboredo acknowledges “la Caixa” Banking Foundation and ADA-University of Navarra for the financial support. This work was partially funded by the Government of Navarra (Grant numbers: PC066- 067 METANOB and PC127-128 METANOB).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectZeines_ES
dc.subjectNanoparticleses_ES
dc.subjectHypoglycemices_ES
dc.subjectGLP-1es_ES
dc.subjectInsulines_ES
dc.subjectDiabeteses_ES
dc.titleOral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in ratses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article under the CC BY-NC-ND licensees_ES
dc.identifier.doi10.1016/j.ijpharm.2022.122255-
dadun.citation.publicationNameInternational Journal of Pharmaceuticses_ES
dadun.citation.startingPage122255es_ES
dadun.citation.volume628es_ES
dc.identifier.pmid36191813-

Files in This Item:
Thumbnail
File
1-s2.0-S0378517322008109-main.pdf
Description
Size
1.37 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.